

# Hossein Borghaei Do

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3629821/publications.pdf>

Version: 2024-02-01

65  
papers

21,070  
citations

147726

31  
h-index

149623

56  
g-index

66  
all docs

66  
docs citations

66  
times ranked

20468  
citing authors

| #  | ARTICLE                                                                                                                                                                                                                                                   | IF   | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1  | Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1627-1639.                                                                                                             | 13.9 | 7,973     |
| 2  | Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. <i>New England Journal of Medicine</i> , 2018, 378, 2093-2104.                                                                                                              | 13.9 | 2,469     |
| 3  | First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2415-2426.                                                                                                                  | 13.9 | 2,145     |
| 4  | Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2020-2031.                                                                                                                          | 13.9 | 1,866     |
| 5  | Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. <i>Lancet Oncology</i> , 2016, 17, 1497-1508.                           | 5.1  | 1,279     |
| 6  | Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. <i>Lancet Oncology</i> , 2017, 18, 31-41.                                                | 5.1  | 845       |
| 7  | Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and 057). <i>Journal of Clinical Oncology</i> , 2021, 39, 723-733. | 0.8  | 444       |
| 8  | Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2969-2979.                                                                                                         | 0.8  | 397       |
| 9  | Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2969-2979.                                                             | 0.8  | 397       |
| 10 | Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 723-733.                                     | 0.8  | 329       |
| 11 | Non-Small Cell Lung Cancer, Version 6.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 515-524.                                                                                                                       | 2.3  | 323       |
| 12 | Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. <i>Lancet Oncology</i> , 2019, 20, 1395-1408.                                                                               | 5.1  | 247       |
| 13 | Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). <i>Cancer</i> , 2020, 126, 260-270.                                                                                                                                    | 2.0  | 202       |
| 14 | 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 124-129.         | 0.5  | 187       |
| 15 | Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. <i>Advances in Therapy</i> , 2019, 36, 2638-2678.                                                                                                                   | 1.3  | 145       |
| 16 | Musashi-2 (MSI2) supports TGF- $\beta$ 2 signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 6955-6960.         | 3.3  | 120       |
| 17 | The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. <i>Cancer</i> , 2020, 126, 3192-3201.                                                                           | 2.0  | 116       |
| 18 | Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. <i>Oncologist</i> , 2017, 22, 1232-1237.                                                                                           | 1.9  | 109       |

| #  | ARTICLE                                                                                                                                                                                                                                                                            | IF  | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. <i>Translational Lung Cancer Research</i> , 2019, 8, 413-428.                         | 1.3 | 95        |
| 20 | Phase 1 dose-escalation study of mirvetuximab soravtansine (<sc>IMGN853</sc>), a folate receptor $\beta$ -targeting antibody-drug conjugate, in patients with solid tumors. <i>Cancer</i> , 2017, 123, 3080-3087.                                                                  | 2.0 | 94        |
| 21 | Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 162-168.                                                      | 0.5 | 90        |
| 22 | Immunotherapy of cancer. <i>European Journal of Pharmacology</i> , 2009, 625, 41-54.                                                                                                                                                                                               | 1.7 | 85        |
| 23 | Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with $\leq$ 1% tumor PD-L1 expression: Results from CheckMate 227.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9001-9001. | 0.8 | 79        |
| 24 | Identifying and managing the adverse effects of immune checkpoint blockade. <i>Journal of Thoracic Disease</i> , 2018, 10, S480-S489.                                                                                                                                              | 0.6 | 78        |
| 25 | Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. <i>Cancer</i> , 2020, 126, 4867-4877.                                          | 2.0 | 69        |
| 26 | Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2577-2584.                                                                                                                                              | 1.9 | 66        |
| 27 | Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients With Advanced Cancer and With Docetaxel in Patients With Advanced Non-small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4116-4123.            | 0.8 | 56        |
| 28 | Phase II Study of Paclitaxel, Carboplatin, and Cetuximab as First Line Treatment, for Patients with Advanced Non-small Cell Lung Cancer (NSCLC): Results of OPN-017. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1286-1292.                                                     | 0.5 | 47        |
| 29 | Safety and efficacy of radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin). <i>Seminars in Nuclear Medicine</i> , 2004, 34, 4-9.                                                                                                                                     | 2.5 | 42        |
| 30 | Nivolumab plus ipilimumab in non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2287-2302.                                                                                                                                                                             | 1.1 | 42        |
| 31 | First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation. <i>Journal of Oncology Practice</i> , 2018, 14, 529-535.                                                                                                                                        | 2.5 | 41        |
| 32 | Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. <i>Cancers</i> , 2021, 13, 3164.                                                                                                                                       | 1.7 | 35        |
| 33 | Targeting KRAS-Mutant Non-small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, 4208-4218.                                                                                                          | 0.8 | 30        |
| 34 | Combining Immunotherapy and Chemotherapy for Non-small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020, 30, 199-206.                                                                                                                                                      | 0.4 | 30        |
| 35 | Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100126.                                                                                              | 0.7 | 24        |
| 36 | Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 <sc>OAK</sc> trial. <i>Cancer</i> , 2022, 128, 3067-3079.                                       | 2.0 | 15        |

| #  | ARTICLE                                                                                                                                                                                                                                                                           | IF  | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Low Level of Blood CD4+ T Cells Is an Independent Predictor of Inferior Progression-free Survival in Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 83-88.                                                                             | 0.2 | 14        |
| 38 | Targeted therapies in solid tumors: Monoclonal antibodies and small molecules. <i>Human Antibodies</i> , 2006, 15, 103-111.                                                                                                                                                       | 0.6 | 13        |
| 39 | Naptumomab estafenatox: a new immunoconjugate. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 273-279.                                                                                                                                                                   | 1.4 | 13        |
| 40 | Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 33.                                                                                                                                        | 1.3 | 13        |
| 41 | Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. <i>Oncologist</i> , 2017, 22, 700-708.                                                                                                    | 1.9 | 11        |
| 42 | Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy. <i>Lung Cancer</i> , 2018, 119, 112-119.                                                                                             | 0.9 | 11        |
| 43 | Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS8577-TPS8577.                                              | 0.8 | 11        |
| 44 | The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 52-59.                                                                                                                                                         | 1.1 | 11        |
| 45 | Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma. <i>Cancer</i> , 2004, 101, 2034-2041.                                                                                                                               | 2.0 | 6         |
| 46 | SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). <i>Clinical Lung Cancer</i> , 2021, 22, 178-186.                                                             | 1.1 | 6         |
| 47 | Bilateral granulosa cell tumors: a novel malignant manifestation of multiple endocrine neoplasia 1 syndrome found in a patient with a rare menin in-frame deletion. <i>The Application of Clinical Genetics</i> , 2015, 8, 69.                                                    | 1.4 | 5         |
| 48 | Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 640-650.e2.                                                                                                                                   | 1.1 | 5         |
| 49 | Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with unresected stage I or II non-small cell lung cancer (NSCLC): KEYNOTE-867.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8597-TPS8597. | 0.8 | 3         |
| 50 | Current issues in adjuvant chemotherapy for resected, stage IB non-small-cell lung cancer. <i>Future Oncology</i> , 2009, 5, 19-22.                                                                                                                                               | 1.1 | 2         |
| 51 | Immunotherapy of lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S395-S396.                                                                                                                                                                                           | 0.6 | 1         |
| 52 | Biomarker Testing in Lung Cancer—What Does It Mean?. <i>JAMA Network Open</i> , 2020, 3, e207171.                                                                                                                                                                                 | 2.8 | 1         |
| 53 | Rituximab-Mediated ADCC Is Augmented by Concomitant Interference with Inhibitory Self-Recognition by Human NK Cells.. <i>Blood</i> , 2005, 106, 2456-2456.                                                                                                                        | 0.6 | 1         |
| 54 | Peripheral Blood CD3+CD4+ and CD3+CD56+ Cell Counts and Circulating Lymphoma Cells Are Significant Predictors of Overall Survival in Newly Diagnosed Follicular Lymphoma.. <i>Blood</i> , 2007, 110, 2607-2607.                                                                   | 0.6 | 1         |

| #  | ARTICLE                                                                                                                                                                                                                   | IF  | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) - Preliminary Results of Subjects with Castleman's Disease from a Phase 1 Study in Selected Hematological Malignancies.. Blood, 2006, 108, 2728-2728.      | 0.6 | 1         |
| 56 | Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. OncoTargets and Therapy, 2009, 2, 251.                                                                                                 | 1.0 | 1         |
| 57 | Overcoming the KRAS resistance mechanism by augmenting antibody-dependent cellular cytotoxicity. Colorectal Cancer, 2012, 1, 273-275.                                                                                     | 0.8 | 0         |
| 58 | Predictors of Distant Recurrence Following Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 243-248.                  | 0.6 | 0         |
| 59 | To Give or Not to Give: Consolidative Durvalumab in EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 2021, 16, 894-896.                                                                                                   | 0.5 | 0         |
| 60 | Vinblastine, Mitoxantrone and Prednisone (MVP) Followed by Involved Field Radiotherapy (IF-XRT) for Early Clinical Stage Hodgkin's Lymphoma: Long Term Follow-Up.. Blood, 2005, 106, 2677-2677.                           | 0.6 | 0         |
| 61 | Phase I Trial of Combination Therapy with 90Y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma.. Blood, 2006, 108, 4710-4710.                                                                 | 0.6 | 0         |
| 62 | Phase I Trial of Combination Therapy with 90Y Ibritumomab Tiuxetan (Zevalin) and Gemcitabine in Patients with Non-Hodgkin's Lymphoma.. Blood, 2007, 110, 4485-4485.                                                       | 0.6 | 0         |
| 63 | CD4 Cell Count of More Than 250/Microl in the Peripheral Blood Is Associated with Improved Overall Survival in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Independent of the aalPI. Blood, 2008, 112, 3775-3775. | 0.6 | 0         |
| 64 | Assessing CD137 (4-1BB) As a Therapeutic Target in B-Cell Neoplasms.. Blood, 2011, 118, 3735-3735.                                                                                                                        | 0.6 | 0         |
| 65 | Phase I Trial of Combination Therapy with 90y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma, Final Report.. Blood, 2012, 120, 2753-2753.                                                   | 0.6 | 0         |